上海新陽(300236.SZ):KrF(248nm)厚膜光刻膠產品成功取得首筆訂單
格隆匯6月30日丨上海新陽(300236.SZ)宣佈,公司自主研發的KrF(248nm)厚膜光刻膠產品近日已通過客户認證,併成功取得第一筆訂單。
KrF(248nm)厚膜光刻膠產品的開發和產業化是公司第三大核心技術——光刻技術的重要方向之一,該次產品認證的通過及訂單的取得,標誌着“KrF(248nm)厚膜光刻膠產品的開發和產業化”取得了成功,為公司在光刻技術領域目標的全面完成奠定了堅實基礎。
光刻膠材料是集成電路製造領域的重要關鍵材料,廣泛應用於350nm-14nm甚至7nm技術節點的集成電路製造工藝。隨着國內晶圓廠建設的不斷增多,以及國外光刻膠巨頭產能受限,供需緊張,國內對光刻膠產品的需求也將快速增長,公司光刻膠產品的訂單取得意義重大,將對公司該類產品的認證及銷售產生積極的作用,有利於公司業務的長期發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.